Home/ Supplements/ Vitamin K/ Dr. Cutler's Advanced Artery Solution II

Dr. Cutler's Advanced Artery Solution II

product on market Capsule True Health Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 50% of ingredients have research evidence
A Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

Vitamin K2 and calcium are studied for their roles in bone health and mineral regulation, while B-vitamins support homocysteine metabolism. Research evidence for these individual nutrients is generally strong, though overall evidence coverage for this specific formulation is limited. The profile maintains a high safety score.

AI-generated summary based on research evidence. Not medical advice.

Label

Product Label

Label for Dr. Cutler's Advanced Artery Solution II
Open Full PDF View on NIH DSLD →
Details

Label Data

3 Capsule(s)
Serving Size
30
Servings
Other Combinations
Product Type
50%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

50 mcg (63% DV)
Within RDA (0.4× RDA) 275 studies (A:9, B:175)
10 mg (500% DV)
7.7× RDA — above typical dose (UL: 100 mg) 114 studies (A:3, B:35)
400 mcg (100% DV)
Within RDA (1.0× RDA) 226 studies (A:10, B:105)
30 mcg (500% DV)
12.5× RDA — above typical dose 139 studies (A:1, B:44)
Calcium
228 mg (23% DV)
Phosphorous
229 mg (23% DV)
47 mg (12% DV)
Within RDA (0.1× RDA) 316 studies (A:8, B:159)
Sodium
48 mg (2% DV)
Market median: 4002.0mg (1 products) 21 studies (A:0, B:2)
EDTA
300 mg
Malic Acid
300 mg
Market median: 600.0mg (7 products) 39 studies (A:2, B:13)
Grapeseed extract
200 mg
Market median: 200.0mg (198 products) 6 studies — no high-quality reviews
50 mg
Market median: 496.0mg (192 products) 20 studies — no high-quality reviews
Market median: 500.0mg (497 products) 135 studies (A:0, B:40)

Other Ingredients

Gelatin Magnesium Stearate Microcrystalline Cellulose
Claims

Label Claims — Verification

Unverified All Other
Unverified Structure/Function
Info

Product Information

Directions for Use

Suggested Use: Take three capsules daily or as directed by your healthcare professional.

Warnings & Precautions

Caution: Consult with your healthcare professional prior to using this product if you are pregnant, nursing, taking medications(s), have a medical condition, or are under the age of 12 years.

KEEP OUT OF REACH OF CHILDREN.

Additional Information

SCIENTIFICALLY FORMULATED DOCTOR APPROVED

STORE IN A COOL, DRY PLACE.

Oral Chelation for Cardiovascular & Bone Health*

This product is manufactured in a NSF GMP registered facility.

Contains the World's Finest Ingredients.

MADE IN U.S.A.

300-TARSC-A

Metadata

Product Details

DSLD Entry Date2012-12-21
Product TypeOther Combinations
FormCapsule
DSLD ID16678
Data Updated2026-04-11
Research

Research Evidence

332
Research Sources
59
Avg Quality
220
Meta Analysis
56
Systematic Review
30
Rct
16
Clinical Trial
3
Guideline
3
Regulatory Source
1
Narrative Review
1
Other
1
Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017 PubMed DOI
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022 PubMed DOI
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013 PubMed DOI
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
View all evidence for Vitamin K →
Compare

Similar Products

View all Vitamin K products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.